The pharmaceutical giant and partner BioNTech announced Friday that they are submitting a formal request to the Food and Drug Administration, just days after the vaccine was shown to be 95% effective.
Albert Bourla, head of the pharmaceutical giant, discusses plans for distributing its vaccine, which it says is 95% effective, and explains the timing of his $5.6 mllion sale of Pfizer stock.
The drugs only need to be taken a few times a year — and may soon be available in many parts of the world. Patients say they are more convenient and less stigmatizing.
As the U.S. prepares for what will likely be the largest vaccination program in its history, the Trump administration plans to loan $590 million to a Connecticut company with a novel technology.
The vaccine was found to be 95% effective in an updated study analysis. Safety data required by the Food and Drug Administration showed no serious concerns, the company said.
With surgical care on the rise globally, researchers worry the energy-consuming procedures will have a negative impact on the climate. But they say there are ways to make them more energy efficient.
People who get more deep sleep appear less likely to develop Alzheimer's. That may be because this phase of sleep allows the brain to clear out waste products.
One of the two leading vaccine candidates requires deep, deep freezing. Here's how communities are working to solve for this and how the new Moderna vaccine could help.
News of the Pfizer COVID-19 vaccine's effectiveness has inspired hope around containing the coronavirus. But polls show that up to two-thirds of Americans say they are unlikely to get a vaccine.
Pfizer's CEO sold $5.6 million worth of stock on Monday. The company says the stock sale was made as part of a preset plan. But NPR found irregularities about when the CEO entered into that plan.
For five decades, NorthPoint Health & Wellness Center has confronted the ways disparities can hurt its patients' health. Community leaders say it's a model for cities facing similar struggles.
The $1.6 billion Novavax contract is one of several Operation Warp Speed agreements issued through a third party, Advanced Technology International, and that hadn't been released.